Corvus Pharmaceuticals, Inc.
CRVS
$7.07
-$0.75-9.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.11M | 9.02M | 8.45M | 8.16M | 7.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.86M | 35.54M | 31.22M | 27.55M | 25.07M |
| Operating Income | -38.86M | -35.54M | -31.22M | -27.55M | -25.07M |
| Income Before Tax | -15.08M | -45.14M | -41.40M | -62.29M | -56.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.08 | -45.14 | -41.40 | -62.29 | -56.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.08M | -45.14M | -41.40M | -62.29M | -56.83M |
| EBIT | -38.86M | -35.54M | -31.22M | -27.55M | -25.07M |
| EBITDA | -38.76M | -35.45M | -31.13M | -27.46M | -24.98M |
| EPS Basic | -0.19 | -0.67 | -0.64 | -0.97 | -0.93 |
| Normalized Basic EPS | -0.12 | -0.42 | -0.40 | -0.60 | -0.58 |
| EPS Diluted | -0.53 | -1.02 | -0.98 | -0.97 | -0.93 |
| Normalized Diluted EPS | -0.13 | -0.43 | -0.41 | -0.60 | -0.58 |
| Average Basic Shares Outstanding | 301.08M | 284.95M | 266.88M | 243.80M | 224.49M |
| Average Diluted Shares Outstanding | 304.11M | 287.97M | 269.91M | 243.80M | 224.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |